Furaquintinib has a certain therapeutic effect on metastatic colorectal cancer that meets the conditions of the indication. According to the data of international and domestic authoritative clinical trials, furaquintinib can reduce the risk of disease by about 30% and can obtain a disease control rate of about 60%. Furaquintinib is suitable for metastatic colorectal cancer that is resistant to irinotecan, fluorouracil-based, oxaliplatin-based chemotherapeutic agents, as well as metastatic colorectal cancer that has received or is unsuitable for anti-epidermal growth factor receptor therapy and anti-vascular endothelial growth factor therapy. The international authority JAMA reported the results of a clinical trial of furaquintinib for metastatic colorectal cancer in 2018, showing that the furaquintinib group could reduce the risk of death by 35%, and could achieve a disease control rate of 62.2%. The Chinese Society of Clinical Oncology (CSCO) reported the results of a clinical trial of furoquinitinib for metastatic colorectal cancer in 2019, which showed that the furoquinitinib group could reduce the risk of death by 41% and could obtain a disease control rate of 70%. Furaquintinib may have adverse reactions such as hypertension, proteinuria, liver function abnormality, diarrhea, platelet reduction, bleeding, etc. It is prohibited for those who are allergic to it, and the risk of bleeding should be concerned about the process of using the drug, and the regular testing of blood routine and coagulation full, so it is recommended that patients must choose and apply under the guidance of doctors, and should not be applied on their own.